Sanofi Consumer Healthcare India Ltd reported a strong performance for the March quarter, with profit and revenue rising sharply on the back of steady domestic growth and a low-base boost in exports.

The company posted a net profit of ₹68 crore, up 35.6% year-on-year, while revenue from operations rose 32.8% to ₹229 crore, according to its latest financial results.

Operating performance also improved during the quarter, with EBITDA rising 38.8% to ₹88.8 crore, while margins expanded to 38.74% from 37.08% a year ago.

Domestic growth, export surge drive revenue

Revenue growth was supported by a recovery in domestic sales and a sharp increase in exports.

“Revenue at ₹2,292 million, a growth of 33%… Domestic sales grew by 15.5% aided by relaunches, while export sales grew by 144% due to a low base,” the company said in its press release.

The company had previously recalled key products such as Allegra Suspension and Combiflam Suspension, which impacted the base in the corresponding quarter last year. Their relaunch has supported domestic growth this quarter.

Management commentary

Himanshu Bakshi, managing director of Sanofi Consumer Healthcare India, said the performance reflects consistent execution across markets.

“Our performance this quarter reflects consistent, disciplined execution across our key markets. Domestic business outpaced the market, delivering both market share gains and volume growth, while exports made a meaningful contribution to overall results,” he said.

He added that the company remains focused on expanding access to self-care solutions.

“Guided by science and driven by purpose, we remain committed to simplifying self-care and making it more accessible and effective for consumers.”

The company’s performance indicates improving traction in core segments, supported by product relaunches and strengthening export demand.

Sanofi Consumer Healthcare India Ltd was carved out as a standalone entity following the demerger of Sanofi India’s consumer healthcare business, which became effective in June 2024. The move was part of the group’s global strategy to separate its consumer healthcare and pharmaceutical businesses, with the new entity now housing key over-the-counter brands such as Allegra, Combiflam and Avil.

Shares of Sanofi Consumer Healthcare India Ltd ended 0.90% higher at ₹4,688 on the NSE on Tuesday. The stock has declined over 5% in the past year, underperforming the Nifty Pharma index, which has gained more than 5% during the same period.